Table 4.
The characteristics of the 33 risk factors in AKI-1 vs AKI-23.
| ID [Name] | AKI-1 n (%) | AKI-23 n (%) | Weighted SHAP Median [IQR] | P value |
|---|---|---|---|---|
| race_2[’African American’] | 918(14.35) | 147(17.03) | 0.0466[0.0364–0.0561] | 0.0415 |
| BMI_4[’>30.0 obese’] | 2655(41.51) | 440(50.99) | 0.0994[0.0731–0.1281] | <0.001 |
| Temperature_4 [’99.5–104.0 Fever’] | 195(3.05) | 57(6.61) | 0.4134[0.3486–0.528] | <0.001 |
| DBP_1[’<80’] | 4812(75.24) | 616(71.38) | 0.0019[0.0005–0.0028] | 0.0161 |
| DBP_3[’90–99 stage 1 hypertension’] | 383(5.99) | 85(9.85) | 0.1313[0.103–0.1624] | <0.001 |
| SBP_3[’140–159 stage 1 hypertension’] | 1208(18.89) | 198(22.94) | 0.0147[0.0094–0.0224] | 0.0054 |
| SBP_4[’>160 stage 2 hypertension’] | 224(3.50) | 47(5.45) | 0.1677[0.1282–0.2377] | 0.0063 |
| Lab13_3[’WBC, more than the standard value’] | 2252(35.21) | 371(42.99) | 0.0507[0.0354–0.0685] | <0.001 |
| Lab2_3[’AST, more than the standard value’] | 1389(21.72) | 214(24.80) | 0.0405[0.028–0.0559] | 0.0451 |
| Lab9_3[’Glucose, more than the standard value’] | 1095(17.12) | 177(20.51) | 0.0685[0.056–0.0887] | 0.0159 |
| CCS131[’Conduction disorders’] | 373(5.83) | 33(3.82) | 0.0032[−0.0034–0.0077] | 0.0198 |
| CCS182[’Septicemia (except in labor)’] | 710(11.10) | 123(14.25) | 0.0509[0.0388–0.069] | 0.0076 |
| CCS202[’Fracture of upper limb’] | 88(1.38) | 20(2.32) | 0.1513[0.1108–0.2049] | 0.0460 |
| CCS219[’Cancer of liver and intrahepatic bile duct’] | 107(1.67) | 28(3.24) | 0.2555[0.1902–0.3351] | 0.0021 |
| CCS271[’Biliary tract disease’] | 236(3.69) | 46(5.33) | 0.1640[0.1218–0.2432] | 0.0246 |
| CCS71[’Skin and subcutaneous tissue infections’] | 482(7.54) | 85(9.85) | 0.0439[0.0322–0.0607] | 0.0209 |
| DRG0[’liver transplant’] | 126(1.97) | 31(3.59) | 0.2544[0.193–0.359] | 0.0032 |
| DRG261[’infect & parasitic disease’] | 110(1.72) | 37(4.29) | 0.3050[0.2228–0.4054] | <0.001 |
| DRG262[’post-op/trauma infect proc’] | 62(0.97) | 23(2.67) | 0.1127[0.0801–0.1479] | <0.001 |
| DRG263[’septicemia & dissem infect’] | 359(5.61) | 66(7.65) | 0.0476[0.0375–0.066] | 0.0207 |
| MED1008[’vasopressin’] | 126(1.97) | 26(3.01) | 0.1191[0.0834–0.1827] | 0.0394 |
| MED1009[’diphenhydramine’] | 3591(56.14) | 503(58.29) | 0.0035[−0.0058–0.0138] | 0.0421 |
| MED1086[’tazobactam’] | 1899(29.69) | 377(43.69) | 0.1613[0.1062–0.23] | <0.001 |
| MED1115[’erythropoietin’] | 69(1.08) | 16(1.85) | 0.1446[0.076–0.2252] | 0.006 |
| MED1142[’acetazolamide’] | 58(0.91) | 5(0.58) | 0.0029[0.0008–0.0077] | 0.0052 |
| MED1152[’albumin’] | 1328(20.76) | 213(24.68) | 0.0415[0.0332–0.057] | 0.0097 |
| MED302[’morphine’] | 2650(41.43) | 411(47.63) | 0.0084[0.0108–0.0217] | 0.0199 |
| MED321[’vancomycin’] | 2005(31.35) | 398(46.12) | 0.1758[0.1231–0.2372] | <0.001 |
| MED516[’glucose’] | 4119(64.40) | 654(75.78) | 0.0644[0.044–0.0799] | <0.001 |
| MED593[’homatropine’] | 34(0.53) | 8(0.93) | 0.0347[0.0187–0.0456] | 0.0097 |
| MED852[’budipine hcl’] | 2176(34.02) | 342(39.630) | 0.0050[−0.0076–0.0163] | 0.0003 |
| MED864[’hydroxyethyl starch 130–0.4’] | 97(1.52) | 30(3.48) | 0.2433[0.195–0.3249] | 0.0004 |
| MED943[’insulin, isophane’] | 235(3.67) | 36(4.17) | 0.0204[0.0112–0.0373] | 0.0130 |
Abbreviations：AKI = acute kidney injury, IQR = interquartile ranges, AKI-1 = AKI stage 1 or mild AKI, AKI-23 = AKI stages 2 and 3 or severe AKI, SHAP = SHapley Additive exPlanations.